Publications Database

Roke Y. et al. (2012)

Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.

Journal of Child and Adolescent Psychopharmacology

22(6), pp. 432-439.

Read Abstract (New Window)

Scahill L. et al. (2006)

A prospective open trial of guanfacine in children with pervasive developmental disorders.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 589-598.

Read Abstract (New Window) Read Full (New Window)

Scahill L. et al. (2001)

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism.

Journal of Child and Adolescent Psychopharmacology

Winter, 11(4), pp, 377-88.

Read Abstract (New Window)

Scahill L. et al. (2001)

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism.

Journal of Child and Adolescent Psychopharmacology

11(4), pp. 377-388

Read Abstract (New Window)

Scahill L. et al. (2017)

Using a patient-centered outcome measure to test methylphenidate versus placebo in children with autism spectrum disorder.

Journal of Child and Adolescent Psychopharmacology

March, 27(2), pp. 125-131.

Read Abstract (New Window) Read Full (New Window)

Schreier H. (1998)

Risperidone for young children with mood disorders and aggressive behavior.

Journal of Child and Adolescent Psychopharmacology

8(1), pp. 49-59

Read Abstract (New Window)

Siegel M. et al. (2014)

Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder.

Journal of Child and Adolescent Psychopharmacology

September, 24(7), pp. 399-402.

Read Abstract (New Window)

Stigler K. A. et al. (2004)

A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.

Journal of Child and Adolescent Psychopharmacology

14(1), pp. 49-56

Read Abstract (New Window)

Stigler K. A. et al. (2009)

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.

Journal of Child and Adolescent Psychopharmacology

19(3), pp. 265-274

Read Abstract (New Window) Read Full (New Window)

Stigler K. A. , Posey D. J. , McDougle C. J. (2004)

Case report: aripiprazole for maladaptive behavior in pervasive developmental disorder.

Journal of Child and Adolescent Psychopharmacology

14(3), pp. 455-463

Read Abstract (New Window)

Stigler K. A. et al. (2010)

Paliperidone for irritability in autistic disorder.

Journal of Child and Adolescent Psychopharmacology

pp. 75-78

Read Extract (New Window)

Stigler K. A. , Posey D. J. , McDougle C. J. (2006)

Ramelteon for insomnia in two youths with autistic disorder.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 631-636

Read Abstract (New Window)

Tachibana M. et al. (2013)

Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders.

Journal of Child and Adolescent Psychopharmacology

23(2), pp. 123-127.

Read Abstract (New Window)

Troost P. et al. (2006)

Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.

Journal of Child and Adolescent Psychopharmacology

pp. 611-619

Read Abstract (New Window)

Valicenti-McDermott M. R. , Demb H. D. (2006)

Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 549-560

Read Abstract (New Window)

van der Gaag R. J. et al. (2005)

A controlled study of formal thought disorder in children with autism and multiple complex developmental disorders.

Journal of Child and Adolescent Psychopharmacology

15(3), pp. 465-476.

Read Abstract (New Window)

Veenstra-VanderWeele J. (2010)

Increase in valproic acid levels during riluzole treatment in an adolescent with autism.

Journal of Child and Adolescent Psychopharmacology

20(2), pp. 163-165

Read Extract (New Window)

Wake R. et al. (2013)

Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.

Journal of Child and Adolescent Psychopharmacology

23(5), pp. 329-336.

Read Abstract (New Window)

Witwer A. N. , Lecavalier L. (2005)

Treatment incidence and patterns in children and adolescents with autism spectrum disorders.

Journal of Child and Adolescent Psychopharmacology

5(4), pp. 671-681

Read Abstract (New Window)

Zuddas A. et al. (2000)

Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.

Journal of Child and Adolescent Psychopharmacology

10(2), pp. 79-90

Read Abstract (New Window)